Volume 7.24 | Jun 25

Newsletter Issue
Cord Blood News 7.24 June 25, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
Amniotic Fluid Stem Cells Provide Considerable Advantages in Epidermal Regeneration: B7H4 Creates a Moderate Inflammation Microenvironment to Promote Wound Repair
Investigators examined the advantages of using human amniotic fluid stem (hAFS) cells in skin wound healing. In vitro, hAFS cells differentiated into keratinocytes (hAFS-K). Like keratinocytes, hAFS-K cells expressed the markers K5, K14, K10 and involucrin; displayed typical cellular structure, including a tonofibril-rich cytoplasm; and constructed a completely pluristratified epithelium in 3D culture. [Sci Rep] Full Article
PUBLICATIONS (Ranked by impact factor of the journal)
Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation for Adult Patients with AML and 11q23/MLL Rearrangement (MLL-R AML)
The authors analyzed the outcome of allogeneic hematopoietic stem-cell transplantation among adult patients reported to the ALWP between 2000 and 2010. They identified 159 patients with 11q23/MLL rearranged acute myeloid leukemia (AML) allografted in first complete remission or CR2, mostly corresponding to t(9;11), t(11;19), t(6;11), and t(10;11) translocations. [Leukemia] Abstract

Postinfarction Functional Recovery Driven by a Three-Dimensional Engineered Fibrin Patch Composed of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells
The authors examined the ability of a three-dimensional engineered fibrin patch filled with human umbilical cord blood-derived mesenchymal stem cells to induce recovery of cardiac function after myocardial infarction. [Stem Cells Transl Med] Abstract

Safety and Efficacy of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells Therapy for Retinal Degeneration
Scientists investigated the safety and efficacy of subretinal injection of human Wharton’s Jelly-derived mesenchymal stem cells on retinal structure and function in Royal College of Surgeons rats. [PLoS One] Full Article

Preserved In Vivo Reconstitution Ability of PBSCs Cryopreserved for a Decade at -80°C
The authors evaluated viability and functions of PBSCs cryopreserved for more than 10 years. Although recovery rate and viability of CD34+ cells were significantly decreased, myeloid differentiation potential and in vivo reconstitution and self-renewal potential of CD34+ cells in a xenogeneic engraftment assay were maintained for more than 10 years. [Bone Marrow Transplant] Abstract

Epigenetic and Molecular Signatures of Cord Blood CD34+ Cells Treated with Histone Deacetylase Inhibitors
The class I and II histone deacetylase inhibitors (HDACIs), valproic acid and scriptaid, were utilized to expand cord blood (CB) CD34+ cells ex vivo. Treatment with individual HDACIs demonstrated significantly unique epigenetic and molecular signatures of CB-hematopoietic stem and progenitor cells. [Vox Sang] Abstract

Effect of Chondrocyte-Derived Early Extracellular Matrix on Chondrogenesis of Placenta-Derived Mesenchymal Stem Cells
Researchers evaluated the effect of decellularized chondrocyte-derived extracellular matrix on the chondrogenesis of human placenta-derived mesenchymal stem cells in a pellet culture system. [Biomed Mater] Full Article

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Overcomes Poor Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC)
Transplant outcomes of patients with AML-MRC have not been reported compared to patients with AML not otherwise specified (AML-NOS). Researchers analyzed transplant outcomes among 147 patients with AML-MRC or AML-NOS who underwent allo-HSCT in a single institution. [Leuk Lymphoma] Abstract

Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood-Derived Cells
The authors provide an update on the clinical and pre-clinical studies using cord blood-derived cells such as mesenchymal stromal cells, endothelial-like progenitor cells, and others. [Biol Blood Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
ERYTECH Announces Two Positive DSMB Reviews
ERYTECH Pharma announced positive safety reviews after the completion of the first cohort in the company’s US Phase I study with ERY-ASP in acute lymphoblastic leukemia, and following the treatment of the first three patients with ERY-ASP in combination with Folfox in its Phase II study in pancreatic cancer. [ERYTECH Pharma] Press Release

Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase III Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
Celator Pharmaceuticals, Inc. announced final induction response rate results in the Phase III study comparing CPX-351 liposome injection to the standard of care regimen in patients with untreated high-risk (secondary) acute myeloid leukemia. [Celator Pharmaceuticals, Inc.] Press Release

Ontario Invests in Better Health and Economic Opportunity through Support for Ontario Institute for Regenerative Medicine
A new $25 million commitment positions Ontario to be an early adopter of new treatments and technologies emerging from research and commercial developments in regenerative medicine. [Ontario Institute for Regenerative Medicine] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells.
Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Society for Hematology and Stem Cells 44th Annual Scientific Meeting 2015
September 17-19, 2015
Kyoto, Japan

Visit our events page to see a complete list of events in the cord blood community.
NEW Regulatory Coordinator – Leukemia Research (Weill Cornell College of Medicine)

NEW PhD Position – Drug Releasing, Nanostructured Biomaterials for Adult Stem Cells (Karlsruhe Institute of Technology)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Postdoctoral Research Scientist – Hematopoietic Stem Cell Self-Renewal and Differentiation (University of Oxford)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Harvard Medical School)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Postdoctoral Scientist – Hematopoietic Stem Cell Transplantation (Indiana University)

Postdoctoral Position – Epigenetic Regulation of Hematopoiesis and Leukemia (Karolinska Institutet)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us